Monitor for any strategic shifts given Satpathy's AI/drug discovery background and Gilliam's med-tech operational experience, but no immediate financial impact expected.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $65.29entry
- T+1 · 13d ago +3.42%α +1.76% · $67.52
- T+5 · 7d ago −3.66%α −3.07% · $62.90
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
10x Genomics appointed Ansuman Satpathy, a Stanford professor and venture partner, and Joseph Gilliam, President/COO of Glaukos Corporation, to its Board of Directors as Class III directors effective October 28, 2026. Gilliam was also appointed Chair of the Audit Committee. This is a routine board expansion with no departure of existing officers.
Key Facts
- Ansuman Satpathy and Joseph Gilliam appointed to the Board of Directors as Class III directors effective October 28, 2026.
- Satpathy is an Associate Professor at Stanford and a venture partner at Wing Venture Capital; Gilliam is President/COO of Glaukos Corporation.
- Joseph Gilliam appointed Chair of the Audit Committee on October 30, 2026, with an additional annual retainer of $25,000.
- Each new director receives standard non-employee director compensation: $60,000 annual cash retainer, a one-time RSU grant of $400,000, and annual RSU grants of $215,000.
- Satpathy's prior scientific advisor agreement (10,000 RSUs) was terminated in October 2026 upon his board appointment.
Financial Impact
Standard non-employee director compensation: $60,000 annual cash retainer plus RSU grants valued at $400,000 (one-time) and $215,000 (annual) per director.
Risk Factors
- No material risks identified; routine board appointment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-068867 |
| Document: 0001628280-26-068867-index-headers.html | 0001628280-26-068867 |
| Document: 0001628280-26-068867-index.html | 0001628280-26-068867 |
| Document: 0001628280-26-068867.txt | 0001628280-26-068867 |
Track record
28 reports on TXG
1 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +8.89% at T+60 after the Aug 19, 2026 report. 2 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $55.40 Now $54.99 −0.74% settles Feb 12
- Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
- Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Mixed 5/10 Entry $59.28 Now $54.99 −7.24% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 2/10 Viewing Entry $65.29 Now $54.99 −15.78% settles Feb 1
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $71.55 Now $54.99 −23.14% settles Jan 21
- Oct 7, 20265w ago SC 13G/A Neutral 2/10 Entry $77.28 Now $54.99 −28.84% settles Jan 5
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $85.71 Now $54.99 −35.84% settles Dec 21
- Sep 22, 20267w ago 144 Neutral 2/10 Entry $75.62 Now $54.99 −27.28% settles Dec 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers